These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24711436)

  • 1. Competing risks analyses: objectives and approaches.
    Wolbers M; Koller MT; Stel VS; Schaer B; Jager KJ; Leffondré K; Heinze G
    Eur Heart J; 2014 Nov; 35(42):2936-41. PubMed ID: 24711436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction to the Analysis of Survival Data in the Presence of Competing Risks.
    Austin PC; Lee DS; Fine JP
    Circulation; 2016 Feb; 133(6):601-9. PubMed ID: 26858290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations of Competing Risks Analysis in Cardio-Oncology Studies:
    Li Y; Sun L; Burstein DS; Getz KD
    JACC CardioOncol; 2022 Sep; 4(3):287-301. PubMed ID: 36213358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
    Tai BC; Chen ZJ; Machin D
    Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
    Austin PC; Fine JP
    Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An introduction to competing risks analysis].
    Pintilie M
    Rev Esp Cardiol; 2011 Jul; 64(7):599-605. PubMed ID: 21621892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.
    Lacny S; Wilson T; Clement F; Roberts DJ; Faris PD; Ghali WA; Marshall DA
    Clin Orthop Relat Res; 2015 Nov; 473(11):3431-42. PubMed ID: 25804881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
    Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
    Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use and interpretation of competing risks regression models.
    Dignam JJ; Zhang Q; Kocherginsky M
    Clin Cancer Res; 2012 Apr; 18(8):2301-8. PubMed ID: 22282466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on an infrequently used quantity in the context of competing risks: The conditional probability function.
    Cabarrou B; Dalenc F; Leconte E; Boher JM; Filleron T
    Comput Biol Med; 2018 Oct; 101():70-81. PubMed ID: 30103091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling two cause-specific hazards of competing risks in one cumulative proportional odds model?
    Ohneberg K; Schumacher M; Beyersmann J
    Stat Med; 2017 Nov; 36(27):4353-4363. PubMed ID: 28833435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.
    Latouche A; Allignol A; Beyersmann J; Labopin M; Fine JP
    J Clin Epidemiol; 2013 Jun; 66(6):648-53. PubMed ID: 23415868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying competing risks regression models: an overview.
    Haller B; Schmidt G; Ulm K
    Lifetime Data Anal; 2013 Jan; 19(1):33-58. PubMed ID: 23010807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Analysis in the Presence of Competing Risks: The Example of Waitlisted Kidney Transplant Candidates.
    Sapir-Pichhadze R; Pintilie M; Tinckam KJ; Laupacis A; Logan AG; Beyene J; Kim SJ
    Am J Transplant; 2016 Jul; 16(7):1958-66. PubMed ID: 26751409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies.
    Oyama MA; Shaw PA; Ellenberg SS
    J Vet Cardiol; 2018 Jun; 20(3):143-153. PubMed ID: 29680637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling competing risks in nephrology research: an example in peritoneal dialysis.
    Teixeira L; Rodrigues A; Carvalho MJ; Cabrita A; Mendonça D
    BMC Nephrol; 2013 May; 14():110. PubMed ID: 23705871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.